compound 1j

Compound 1j is a designation used for multiple distinct small molecule research candidates in medicinal chemistry literature. One prominent entity referred to as compound 1j is 4-(4-fluorophenyl)-6-oxo-2-thioxohexahydropyrimidine-5-carbonitrile, a hexahydropyrimidine derivative that functions as an inhibitor of neutral sphingomyelinase 2 (nSMase2). This enzyme is critical for exosome biogenesis and ceramide signaling, processes linked to neurodegeneration and cancer progression. In preclinical models, this version of compound 1j showed an IC50 of 1.88 μM against Bacillus cereus sphingomyelinase. Another entity identified as compound 1j is a benzimidazole derivative containing a benzohydrazide-hydrazone moiety, which has been studied as a potent acetylcholinesterase (AChE) inhibitor for the potential treatment of Alzheimer's disease. Both compounds are currently in the early research or preclinical stages and are not associated with commercial pharmaceutical development.

Other names

4-(4-fluorophenyl)-6-oxo-2-thioxohexahydropyrimidine-5-carbonitrile